Back to Search
Start Over
Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors
- Source :
- Journal for Immunotherapy of Cancer, Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
- Publication Year :
- 2021
- Publisher :
- BMJ Publishing Group, 2021.
-
Abstract
- BackgroundThe modified Glasgow Prognostic Score (mGPS) is a composite biomarker that uses albumin and C reactive protein (CRP). There are multiple immune checkpoint inhibitor (ICI)-based combinations approved for metastatic renal cell carcinoma (mRCC). We investigated the ability of mGPS to predict outcomes in patients with mRCC receiving ICI.MethodsWe retrospectively reviewed patients with mRCC treated with ICI as monotherapy or in combination at Winship Cancer Institute between 2015 and 2020. Overall survival (OS) and progression-free survival (PFS) were measured from the start date of ICI until death or clinical/radiographical progression, respectively. The baseline mGPS was defined as a summary score based on pre-ICI values with one point given for CRP>10 mg/L and/or albuminResults156 patients were included with a median follow-up 24.2 months. The median age was 64 years and 78% had clear cell histology. Baseline mGPS was 0 in 36%, 1 in 40% and 2 in 24% of patients. In UVA, a baseline mGPS of 2 was associated with shorter OS (HR 4.29, 95% CI 2.24 to 8.24, pConclusionThe mGPS is prognostic in this cohort of patients with mRCC treated with ICI as monotherapy or in combination. These results warrant external and prospective validation.
- Subjects :
- 0301 basic medicine
Oncology
Male
Cancer Research
medicine.medical_specialty
medicine.medical_treatment
Immunology
Glasgow Outcome Scale
Prognostic score
03 medical and health sciences
0302 clinical medicine
Renal cell carcinoma
Internal medicine
Immunotherapy Biomarkers
medicine
Immunology and Allergy
tumor microenvironment
Humans
Neoplasm Metastasis
Carcinoma, Renal Cell
Immune Checkpoint Inhibitors
RC254-282
Retrospective Studies
Pharmacology
biology
business.industry
C-reactive protein
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Histology
Immunotherapy
Middle Aged
medicine.disease
Kidney Neoplasms
inflammation mediators
030104 developmental biology
030220 oncology & carcinogenesis
tumor biomarkers
Cohort
biology.protein
Molecular Medicine
Biomarker (medicine)
Female
immunotherapy
business
urological neoplasms
Clear cell
Subjects
Details
- Language :
- English
- ISSN :
- 20511426
- Volume :
- 9
- Issue :
- 7
- Database :
- OpenAIRE
- Journal :
- Journal for Immunotherapy of Cancer
- Accession number :
- edsair.doi.dedup.....644c74234b1adc896eba4ecac1130a5b